SCHEMBL3136286

SCHEMBL3136286

COC(=O)CCc1cc(Cl)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 3/20 0.50
HIF1A Q16665 3/20 0.50
ALOX15 P16050 3/20 0.50
CYP3A4 P08684 3/20 0.50
LMNA P02545 2/20 0.50
SLC22A1 O15245 1/20 0.50
USP2 O75604 1/20 0.50
HSP90AA1 P07900 1/20 0.50
HSPD1 P10809 1/20 0.50
HSPA5 P11021 1/20 0.50
IDO1 P14902 1/20 0.50
ALOX12 P18054 1/20 0.50
CASP1 P29466 1/20 0.50
HTT P42858 1/20 0.50
BLM P54132 1/20 0.50
HSPE1 P61604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14609800 0.85 MAPT (0.54) MEN1KMT2AMAPTCYP3A4LMNA
SCHEMBL16120741 0.84 MTNR1A (0.46) MEN1KMT2AMAPTHPGDHIF1A
SCHEMBL15071460 0.84 MAPT (0.49) MEN1KMT2AMAPTCYP3A4LMNA
SCHEMBL31306792 0.83 EGFR (0.55) MEN1KMT2AMAPTHPGDHIF1A
SCHEMBL4034721 0.83 EGFR (0.55) MEN1KMT2AMAPTHPGDHIF1A
SCHEMBL4608717 0.83 MAPT (0.48) MEN1KMT2AMAPTCYP3A4LMNA
SCHEMBL4609201 0.83 MAPT (0.48) MEN1KMT2AMAPTCYP3A4LMNA
SCHEMBL11532393 0.82 MAPT (0.57) MAPTHPGDCYP3A4HTTEGFR
SCHEMBL27383378 0.82 AMY1A (0.46) KMT2AMAPTHPGDHIF1AALOX15
SCHEMBL7073191 0.81 MAPT (0.47) MEN1KMT2AMAPTCASP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma ASTRAZENECA AB (SE) 2010-04-01 US disclosed
CN-101351448-A Novel 1-benzyl-4-piperidinamines for the treatment of COPD and asthma ASTRAZENECA AB (SE) 2009-01-21 CN disclosed
EP-1945613-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA AstraZeneca AB (SE) 2008-07-23 EP disclosed
WO-2007053082-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA ASTRAZENECA AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma CCR1, CCR4, CCR10 MEN1 4733/4885KMT2A 2792/4885MAPT 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.